YR-001 is under clinical development by YIRUI Pharmaceutical Technology and currently in Phase I for Psoriasis. According to GlobalData, Phase I drugs for Psoriasis have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how YR-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
YR-001 overview
YR-001 is under development for the treatment of atopic dermatitis, inflammatory bowel disease, alopecia and psoriasis. The drug candidate is a small molecule which acts by targeting ion channel and is administered topically and orally.
YIRUI Pharmaceutical Technology overview
YIRUI Pharmaceutical Technology (YIRUI Pharma) focuses on providing therapeutic solutions for the treatment and prevention of chronic skin diseases, autoimmune disorders, diabetes complications and other serious diseases. YIRUI Pharma is headquartered in Hangzhou, Zhejiang, China.
For a complete picture of YR-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.